An Open-Label, Phase II Study to Determine the Immunologic Correlates of Pembrolizumab-Mediated Tumor Regression in Subjects With Advanced Melanoma (KEYNOTE-161)
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- Acronyms KEYNOTE-161
- Sponsors Merck Sharp & Dohme
- 17 Oct 2019 Status changed from active, no longer recruiting to discontinued.
- 16 May 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated